Clinical Trial Search

Primary: Change in Hamilton Depression Scale (HAMD-17) Total Score From Baseline — 23.2; 22.4; 11.8; 13.2 Points on HAMD-17 scale — p=0.0119

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 — -0.71; 0.31 Percent — p=<0.001

Primary: Percent Time With Intragastric pH>4 During the First 4 Hours Following Administration on Day 4 of Treatment — 53.265; 46.933; 17.215 Percentage of Time

Primary: Change in Toronto Western Spasmodic Torticollis Rating Scale Total Score From Baseline — -16.21; 42.48; 25.81; -11.40 points on a scale

Primary: Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks) — -0.69; -0.85; -0.75; -8.97 mm Hg — p=0.0008

Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9. — -16; -9 units on scale

Primary: Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. — 1390.4; 1895.2 mIU/mL

Primary: Percent Change From Baseline in Total Lesion Counts at Week 12. — -64; -41 % of change

Primary: Safety and Tolerability in This Patient Population (Narcolepsy, OSAHS, SWSD) Over Time (up to 2 Years) — 667 Participants

Primary: Change From Baseline in Percent Atheroma Volume (PAV) to Month 18 — 40.593; 40.422; 41.013; 40.182 percent (absolute change)

Primary: Change in Glycosylated Haemoglobin A1c (HbA1c) — -1.790; -1.517 percentage (%) of total haemoglobin

Primary: Overall Survival — 11.7; 12.2; 11.4; 11.5 months — p=0.4921

Primary: First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per…

Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559